Monday, August 31, AstraZeneca has begun a late-stage study of its COVID-19 vaccine candidate, AZD1222, with 30,000 participants.
The 30,000 participants aged above 18 are being randomized to receive two doses of either AZD1222 or saline control, four weeks apart, with twice as many participants receiving the potential vaccine as the saline control, the company said.
AZD1222 is already undergoing late-stage clinical trials in Britain, Brazil, and South Africa, with additional trials planned in Japan and Russia. The trials, together with the U.S. Phase III study, aim to enroll up to 50,000 participants globally.
The trial is being conducted under the U.S. government’s Operation Warp Speed program, which aims to accelerate the development, manufacturing, and distribution of vaccines and treatments for COVID-19.